Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3  by Paulson, H.L et al.
Neuron, Vol. 19, 333±344, August, 1997, Copyright 1997 by Cell Press
Intranuclear Inclusions
of Expanded Polyglutamine Protein
in Spinocerebellar Ataxia Type 3
H. L. Paulson,*²# M. K. Perez,* Y. Trottier,§ glutamine repeat appears to confer upon the disease
protein a toxic gain of function that is selectively deleteri-J. Q. Trojanowski,³ S. H. Subramony,‖ S. S. Das,*
ous to neurons (Housman, 1995; Ross, 1995; Bates,P. Vig,‖ J.-L. Mandel,§ K. H. Fischbeck,²
1996; MacDonald and Gusella, 1996). Theoretical mod-and R. N. Pittman*
els and a growing body of experimental evidence sug-*Department of Pharmacology
gest that expanded glutamine repeats may alter protein²Department of Neurology
interactions, but precisely how this causes neurodegen-³Department of Pathology
eration is unknown (Perutz et al., 1994; Li et al., 1995;University of Pennsylvania School
Stott et al., 1995; Bao et al., 1996; Burke et al., 1996; Ikedaof Medicine
et al., 1996; Kahlem et al., 1996; Kalchman et al., 1997;Philadelphia, Pennsylvania 19104
Wanker et al., 1997).§ Institut de Genetique et de Biologie
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diseases are increasingly focussed on the glutamineFrance
repeat itself (Bates, 1996; Perutz, 1996). First, the dis-‖Department of Neurology
ease proteins are entirely dissimilar outside of the poly-University of Mississippi
glutamine tract. Second, disease severity increases withJackson, Mississippi 38677
longer glutamine repeats in each disease (although the
threshold repeat length for developing disease differs
slightly for each disease). Third, and most important,Summary
several transgenic models employing protein fragments
with an expanded glutamine repeat have yielded neuro-The mechanism of neurodegeneration in CAG/poly-
degenerative phenotypes (Ikeda et al., 1996; Mangiariniglutamine repeat expansion diseases is unknown but
et al., 1996). Experimental results from several labora-is thought to occur at the protein level. Here, in studies
tories are consistent with a model in which expandedof spinocerebellar ataxia type 3, also known as Ma-
polyglutamine adopts a ªpathologic conformationº (Trot-chado-Joseph disease (SCA3/MJD), we show that the
tier et al., 1995b) and engages in inappropriate protein±disease protein ataxin-3 accumulates in ubiquitinated
protein interactions, perhaps even including aggrega-intranuclear inclusions selectively in neurons of af-
tion of the disease protein (Ikeda et al., 1996).fected brain regions. We further provide evidence in
Protein aggregation mediated by the expanded gluta-vitro for a model of disease in which an expanded
mine domain is a compelling model for the molecularpolyglutamine-containing fragment recruits full-length
basis of disease, in part because it is so common aprotein into insoluble aggregates. Together with re-
theme in other neurodegenerative diseases. But whereascent findings from transgenic models, our results sug-
well defined pathologic structures support theories ofgest that intranuclear aggregation of the expanded
aggregation in, for example, Alzheimer's disease, noneprotein is a unifying feature of CAG/polyglutamine dis-
of the CAG/polyglutamine diseases is known to haveeases and may be initiated or catalyzed by a gluta-
neuropathologic changes that support a model of aggre-mine-containing fragment of the disease protein.
gation. In addition, no adequate theory has yetexplained
why, in each CAG/polyglutamine disease, only selective
Introduction
brain regions are affected, despite widespread expres-
sion of the disease proteins.
A growing number of neurodegenerative diseases are
As a model for the CAG/polyglutamine repeat dis-
now known to be caused by an expanded CAG trinu-
eases, we have chosen to study spinocerebellar ataxia
cleotide repeat that encodes polyglutamine in the dis-
type 3, also known as Machado-Joseph disease (SCA3/
ease protein (Bates, 1996; Zoghbi, 1996; Paulson and MJD; Rosenberg, 1992). This CAG/polyglutamine repeat
Fischbeck, 1996). To date, the list includes Huntington's disorder may be the most common dominantly inherited
disease (HD), spinal and bulbar muscular atrophy, den- ataxia worldwide (Maciel et al., 1995; Maruyama et al.,
tatorubral-pallidoluysian atrophy, and five dominantly 1995; Matilla et al., 1995; Ranum et al., 1995; Schols et
inherited ataxiasÐspinocerebellar ataxia (SCA) types al., 1995; Durr et al., 1996). The clinical features of SCA3/
1±3, 6, and 7 (La Spada et al., 1991; Huntington's Disease MJD vary, but typically include ataxia together with bul-
Collaborative Research Group, 1993; Orr et al., 1993; bar, extrapyramidal, and pyramidal signs. The most fre-
Kawaguchi et al., 1994; Koide et al., 1994; Nagafuchi et quent pathologic findings are degeneration within the
al., 1994; Imbert et al., 1996; Lindblad et al., 1996; Pulst deep basal ganglia, the brainstem, the spinal cord, and,
et al., 1996; Sanpei et al., 1996; Zhuchenko et al., 1997). to a lesser extent, the cerebellum (Sachdev et al., 1982;
These disorders are thought to share a common patho- Yuasa et al., 1986; Takiyama et al., 1994). The disease
genesis occurring at the protein level. Expansion of the gene MJD1 encodes an intracellular protein of unknown
function, ataxin-3, which with a predicted molecular
weight of 42 kDa is the smallest of the polyglutamine# To whom correspondence should be addressed. Present address:
disease proteins (Kawaguchi et al., 1994). The CAG/Department of Neurology, University of Iowa Hospitals, Iowa City,
IA 52242. glutamine repeat lies near the carboxyl terminus, where
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Figure 1. Western Blot for Ataxin-3
Ataxin-3 antiserum specifically recognizes
normal and expandedrepeat ataxin-3. Shown
are results with human cell lines probed se-
quentially with immune (a) and preimmune (b)
serum. The bracket indicates normal ataxin-3,
which varies in size because of normal CAG
repeat length polymorphism, and the arrow
indicates expanded ataxin-3 in two SCA3/
MJD lymphoblastoid cell lines (SCA3-LCL).
Normal and expanded CAG repeat lengths
are noted in parentheses for the SCA3/MJD
LCLs. Abbreviations for cell lines are HeLa
(HeLa cells), hNT2 (differentiated human
N-Tera2 neurons), and cLCL (control lympho-
blastoid lines).
it is normally 12±37 repeats and becomes expanded to there is strong immunostaining for ataxin-3 within the
nuclei of neurons (Figure 2). In individual neurons, this61±84 repeats in affected individuals.
In this paper, we present evidence for aberrant local- staining takes the form of one to three spherical intra-
nuclear structures varying in size from 0.5 to z6 mm inization and probable aggregation of this polyglutamine
disease protein in human disease tissue. Our studies of diameter. In some neurons, the inclusion spans more
than half the diameter of the nucleus, but the most com-SCA3/MJD brain demonstrate that ataxin-3, normally
a predominantly cytoplasmic protein, accumulates in monly observed pattern is a singlet or doublet structure
near to, yet clearly distinct from, the hematoxylin-ubiquitinated nuclear inclusions (NI) that are found se-
lectively in neurons known to be affected by the disease stained nucleolus (Figure 2d). NI were seen in both etha-
nol- and formaldehyde-fixed tissue, with short and longprocess. The results take on an added significance in
light of recent findings showing neuronalNI in transgenic postmortem intervals. Staining was not observed with
preadsorbed or preimmune serum or in the absence ofmodels of other polyglutamine diseases (Davies et al.,
1997; H. Orr and H. Zoghbi, personal communication) primary serum. The inclusions were not autofluorescent,
thus distinguishing them from the inclusions seen in theand suggest that, although the various polyglutamine
disease proteins normally may be present in different rare disorder, neuronal intranuclear inclusion disease
(NIID; Palo et al., 1984; Garen et al., 1986; Weidenheimcellular compartments, the nucleus is a primary site of
pathogenesis for this class of diseases. In further studies and Dickson, 1995).
NI were seen only in neurons and never in glial cells,in vitro, we present evidence supporting a model of
disease in which full-length disease protein is recruited despite the fact that many glial cells stain for ataxin-3
in normal and in diseased brain (Paulson et al., 1997).into aggregates by a polyglutamine fragment.
NI were found most frequently in neurons of the ventral
pons, a primary target region in SCA3/MJD (Sachdev etResults
al., 1982; Yuasa et al., 1986; Takiyama et al., 1994). They
were also seen, less frequently, in other regions knownNuclear Inclusions (NI) of Ataxin-3 in Neurons
of SCA3/MJD Brain to be affected in disease: substantia nigra, globus pal-
lidus, dorsal medulla, and dentate nucleus. NI were notIn an earlier study, we generated antiserum specific for
the MJD1 gene product ataxin-3 (Paulson et al., 1997). found in regions typically spared in disease, including
cerebral cortex, hippocampus, striatum, and the Pur-Figure 1 shows a representative immunoblot with this
antiserum, also the principal immune serum used in the kinje cell layer of the cerebellum. Even though it is gener-
ally not thought to be a major target in disease, thecurrent study. With this antiserum, we previously dem-
onstrated that both normal and expanded repeat inferior olivary complex contained infrequent NI.
To confirm that these structures were specific to theataxin-3 are expressed widely in diseased brain and
throughout the body. In immunohistochemical studies disease state, we quantitated NI in the ventral pons of
four SCA3/MJD brains and five control brains (Table 1).of normal brain, ataxin-3 was localized to neuronal and
nonneuronal cells in a predominantly, but not exclu- NI were present in all four SCA3/MJD brains, with one
or more NI found in slightly less than half the neurons.sively, cytoplasmic distribution. Staining also extended
into neuronal processes and occasionally was observed NI were absent from all five controls. The frequency of
NI in several other affected regions was lower but notwithin the nuclei of neurons in a faint punctate pattern.
In diseased brain, the subcellular distribution of quantitated.
To confirm that the inclusions contain ataxin-3,ataxin-3 differs in at least one important respect: in sev-
eral brain regions that are known targets of disease, we performed double labeling immunofluorescence in
Intranuclear Inclusions in SCA3/MJD
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Figure 2. Nuclear Inclusions (NI) Containing
Ataxin-3 in SCA3/MJD Brain
Ataxin-3 immunohistochemical staining in
ventral pons from diseased brain ([a],[c], and
[d]) demonstrates immunoreactive NI in neu-
rons (arrows). At higher magnification, NI are
distinct from, but often adjacent to, the hema-
toxylin-stained nucleolus (arrowhead in [d]).
In control pons (b), NI were not seen, but note
the normal predominantly cytoplasmic immu-
nostaining for ataxin-3. Preadsorbed control
is shown in (e). NI were also observed in other
brain regions known be affected in disease
(not shown). Magnifications before publica-
tion, 3003 ([a] and [b]), 6003 (c), 15003 (d),
and 4003 (e).
which the polyclonal ataxin-3 antiserum was paired with ataxin-3 throughout the inclusion (Figure 3). As with
ataxin-3 immunostaining, ubiquitin immunostaining dem-a monoclonal antibody (MAb) specific for ataxin-3 (1H9)
or with MAb 1C2, the polyglutamine-specific antibody onstrated that NI size varies considerably, in somecases
nearly fully occupying the nucleus (Figure 4a; see alsothat preferentially recognizes expanded glutamine do-
mains (Trottier et al., 1995b). In diseased brain, both the lower portion of Figure 3). Again, brain regions that
are known targets of disease showed intranuclear ubi-MAbs labeled the same nuclear structures as did the
polyclonal antiserum (Figure 3). Serial confocal images quitin staining, whereas unaffected regions did not.
In a systematic survey of brain regions, ubiquitin-posi-taken through an inclusion demonstrated the immuno-
fluorescence signal in all focal planes, indicating that tive spherical bodies were found only in neurons and
were nearly always intranuclear; only two clearly cyto-ataxin-3 is present throughout these structures (Figure
3). Staining of NI with 1C2 further confirms that the plasmic ubiquitin inclusions were seen in twothoroughly
examined SCA3/MJD brains. It is important to note,pathologic expanded glutamine domain is present
within these inclusions. however, that ubiquitination in SCA3/MJD brain is not
limited to NI. In affected regions, for example, densely
immunoreactive deposits were often seen near neuronsAtaxin-3 Inclusions Are Ubiquitinated
Ubiquitination is a common featureof many neuropatho- (Figure 4c). We do not know whether these represent the
residue of dead or dying neurons or ubiquitin-positivelogic structures, such as the Lewy body of Parkinson's
disease (Lowe et al., 1993; Galvin et al., 1997). Its pres- nonneuronal cells; staining of adjacent thin sections with
ataxin-3 antisera indicated that many of these depositsence in neuropathologic structures is thought to reflect
aberrant protein folding or degradation. We therefore contain ataxin-3 (not shown). Diffuse cytoplasmic label-
ing for ubiquitin was also seen in some neurons of thedetermined whether NI also contain ubiquitin. In coim-
munofluorescence studies, ubiquitin colocalized with substantia nigra and cervical cord. Lastly, many larger
ubiquitin-positive structures resembling corpora amyla-
cea were observed in the globus pallidus, pons, andTable 1. Quantitation of Ataxin-3 Nuclear Inclusions in SCA3/
medulla (not shown). However, since corpora amylaceaMJD Pons
are also seen as a normal feature of aging brain (Dickson
Tissue Neurons with Inclusions (% 6 SD) et al., 1990), their relevance to the disease process is
SCA3/MJD (N 5 4)a 44.6% 6 17.9%c uncertain.
Control (N 5 5)b 0.0% 6 0.0% Many ubiquitin-positive pathologic structures contain
antigenic determinants from cytoskeletal proteins or cy-afrom three unrelated families with molecularly confirmed SCA3/
MJD toskeletal-associated proteins. However, immunohisto-
bthree controls without neurologic disease and two with Alzheimer's chemical staining with a panel of antibodies for such
disease as irrelevant disease controls proteins was negative, suggesting that the NI of SCA3/
cz20% of positive neurons had more than one inclusion
MJD do not contain these proteins (Table 2). Particularly
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Figure 3. Co immunofluorescence Analysis
Confirming the Presence of Ataxin-3,
Expanded Polyglutamine, and Ubiquitin
within NI
Shown are confocal coimmunofluorescence
images of SCA3/MJD pontine neurons (top
three rows) and a control pontine neuron (bot-
tom row) labeled with ataxin-3-specific MAb
1H9, polyglutamine-specific MAb 1C2, or
anti-ubiquitin (left), together with ataxin-3
polyclonal antiserum (center). Composite im-
ages (right) demonstrate colocalization of la-
bel in NI in SCA3/MJD neurons; note that 1C2
weakly labels NI, yielding a green instead of
a yellow composite image. The punctate cy-
toplasmic labeling seen in the rhodamine im-
ages is largely autofluorescence, is seen in
both diseased and control neurons, and
roughly defines the nuclear border. All sets
of panels are summed images through the
entire inclusion, except the anti-ubiquitin
panels (third row from the top), which repre-
sent a single 0.5 mm focal plane through the
center of a large inclusion, demonstrating
that immunolabel is present deep within the
structure.
notable is the absence of staining for neurofilament encoding either full-length ataxin-3 or a carboxy-termi-
nal fragment of the protein consisting of the glutamineproteins, a common component of many ubiquitinated
structures, including Lewy bodies and the inclusions of repeat with short flanking sequences. For these studies,
the normal and expanded polyglutamine tracts were 27NIID (Palo et al., 1984; Lowe et al., 1993; Galvin et al.,
1997). and 78 repeats, respectively. In transfected cells, we
observed diffuse cytoplasmic staining for full-length
ataxin-3 with a normal or expanded glutamine repeat,Intracellular Aggregates Formed by an Expanded
Glutamine Fragment as well as for the truncated protein containing a normal
repeat (Figure 5A). This result is consistent with ourThe presence in SCA3/MJD of NI containing ataxin-3
suggested that expanded ataxin-3 aggregates within observation that endogenous ataxin-3 has a predomi-
nantly cytoplasmic distribution in several human cellthe nucleus. To model this in vitro, we transfected human
kidney epithelial 293T cells with expression constructs lines (unpublished data).
Figure 4. Ubiquitin Immunohistochemistry
NI in affected SCA3/MJD brain regions immu-
nolabel with anti-ubiquitin antiserum. Images
show a diseased pons showing a single large
intranuclear inclusion (arrow in [a]); a control
pons labeled with anti-ubiquitin antiserum (b);
and a diseased pons demonstrating ubiqui-
tin-positive deposits that are seen in affected
brain regions (arrowheads in [c]), often near
neurons containing NI (arrows). Magnifica-
tions before publication, 4003 ([a] and [b])
and 6003 (c).
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Table 2. Antibody Immunolabeling of Nuclear Inclusions
Antiserum Antigen Dilution Inclusion Staining
anti-ataxin-3 ataxin-3 (polyclonal) 2,500 111
1H9 ataxin-3 (mAb) 100 11
2B6 ataxin-3 (mAb) 100 2
1C2 TBP/polyGln 400 11
1C2 expanded polyGln 15,000 1
anti-ubiquitin polyubiquitin 500 111
anti-actin actin 100 2
bTubulin tubulin 1,000 2
MAP1B MAP 5 500 2
AP14 MAP 2 neat 2
anti-NFL NFL, Pind/tail 2,000 2
TA51 NFH,P1/tail within MPR neat 2
RMdO9 NFH, P2/tail within MPR neat 2
RM024 NFH P111/tail within MPR 10 2
PHF-6 paired helical filament 5,000 2
anti-vimentin vimentin 100 2
anti-peripherin peripherin 100 2
anti-desmin desmin neat 2
AE3 keratin 100 2
AE1 keratin neat 2
GA5 GFAP 500 2
Abbreviations: TBP, TATA-binding protein; MAP, microtubule associated protein; NFL and NFH, neurofilament light and heavy chains; P111,
heavily phosphorylated epitope; P1, lightly phosphorylated epitope; P-, non- or poorly phosphorylated epitope; Pind, phosphorylation-
independent epitope; MPR, multiphosphorylation repeat; GFAP, glial fibrillary acidic protein.
In contrast, truncated protein with an expanded re- the top of the stack and separating gels (Figure 6A).
Truncated ataxin-3 with a normal repeat does not formpeat did not distribute diffusely within the cytoplasm
but rather localized to two distinct subcellular struc- such complexes, although it may form SDS-resistant
dimers. Likewise, full-length protein with a normal ortures: large cytoplasmic (and occasionally nuclear)
spherical bodies that resemble vacuoles under phase expanded repeat does not form high molecular weight
complexes. However, when coexpressed with an ex-contrast optics and smaller intranuclear and perinuclear
clusters (Figure 5A). Greater than 97% of cells trans- panded glutamine fragment, full-length ataxin-3 is re-
cruited into insoluble complexes (Figure 6B). This wasfected with the expanded polyglutamine fragment dis-
played the larger spherical structures, and many cells determined by showing, in coexpression experiments,
that the high molecular weight complexes now becomedisplayed both structures. The larger structures concen-
trated the lysosomal marker Lysotracker DND-99 and recognizable by antibodies to epitopes present only in
the full-length, but not the truncated, protein (resultsthus may represent acidotropic vesicles, possibly lyso-
somal in origin (data not shown). The smaller ataxin-3 with the ataxin-3 specific MAb 2B6 are shown; ataxin-3
antiserum gave similar results in separate experiments).inclusions did not appear vesicular, and were most in-
tensely immunolabeled by the polyglutamine-specific Significantly, recruitment of the full-length ataxin-3 into
aggregates occurred toan appreciable extent only whenMAb 1C2. Confocal imaging confirmed that these
smaller clusters were localized to the intranuclear and an expanded glutamine repeat was present in the full
protein (Figure 6B). These results suggest that a patho-perinuclear space (Figure 5B). Although they are smaller
than the NI seen in diseased brain, their presence indi- logic (expanded) glutamine fragment can serve to initi-
ate or catalyze aggregation of the full-length protein.cates that truncated ataxin-3 can be transported to the
nucleus, where it may form microaggregates. Moreover, the probability that this will occur is depen-
dent upon the length of the glutamine repeat within theOthers have shown that expression of an expanded
glutamine fragment of ataxin-3 is cytotoxic to COS cells full protein.
Next, we determined whether, along with electro-(Ikeda et al., 1996). Similarly, we find that truncated
ataxin-3 with an expanded glutamine repeat induces phoretic evidence for recruitment, there were corre-
sponding changes in the cellular distribution of full-cell death in 293T cells (Figure 5C). The cytotoxicity we
observe, however, is less marked than that previously length ataxin-3. To do this, we expressed full-length
ataxin-3 together with truncated protein containing anreported, even though the truncated ataxin-3 construct
and repeat length used by us is similar. In our hands, expanded repeat, and then performed coimmunofluo-
rescence with antibodies that distinguished the two (Fig-for example, many transfected cells survive severaldays
and continue to express the cotransfected marker gene ure 7). In one set of experiments, MAb 2B6 and anti-
hemagglutinin (HA) antibody were used to distinguishlacZ.
full length ataxin-3 from a tagged truncated protein, and
in a second set of experiments, the two proteins wereRecruitment of Ataxin-3 into Aggregates
When expressed in transfected cells, truncated ataxin-3 separately epitope tagged and distinguished with anti-
myc and anti-HA antibodies. When coexpressed withwith an expanded repeat forms insoluble high molecular
weight complexes that electrophorese on SDS gels at the truncated protein, full-length ataxin-3 no longer
Neuron
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Figure 5. Immunofluorescence of 293T Cells Transfected with
Ataxin-3 Constructs
(A) Confocal images of transfected cells expressing full length
ataxin-3 with 27 or 78 glutamine repeats (ataxin27 and ataxin78) or a
carboxy-terminal fragment of the protein containing 27 or 78 repeats
(HA-Q27 and HA-Q78) and immunolabeled with the ataxin-3 specific
MAb 2B6 (ataxin27 and ataxin78 images) or with anti-HA (HA-Q27
and HA-Q78 images). Diffuse cytoplasmic staining is seen in all
cases except HA-Q78, which localizes to discrete perinuclear spher-
ical structures (arrow) and to smaller perinuclear and intranuclear
clusters (see [B]). In untransfected cells, faint cytoplasmic staining
is seen with 2B6, due to endogenous ataxin-3 (visible in the ataxin27
image).
(B) Confocal images of an untransfected cell (left) and of a
transfected cell (right series) expressing HA-Q78 and displaying
perinuclear and intranuclear clusters immunolabeled with 1C2 MAb
(1:15,000 dilution). The far left image in the series is a summed
image of the cell, and the remaining images represent three focal
planes (0.5 mm) through the cell, demonstrating intranuclear (arrows)
and perinuclear clusters.
(C) Cell death is induced by HA-Q78 but not other ataxin-3 con-
structs (inset). Results represent quantitation from 10 randomly se-
lected fields for each construct. Results are representative of three
experiments.
distributed diffusely in the cytoplasm. Instead, it coloca- were obtainedwith expanded ataxin-3. In control experi-
ments, neither of two irrelevant proteins, b-galacto-lized with truncated protein to the same large spherical
perinuclear structures that are formed in cells express- sidase and calbindin, colocalized to the subcellular
ataxin-3 structures (Figure 7; data not shown). The re-ing just the truncated protein. In contrast to the gel
electrophoresis results, which showed that only ex- sults are consistent with a model in which recruitment
is mediated through the glutamine domain of the full-panded repeat ataxin-3 tends to be recruited into insol-
uble complexes, the coimmunofluorescence studies length protein and occurs even with a glutamine repeat
of normal length.demonstrate that both normal and expanded repeat
ataxin-3 are recruited to the spherical structures by a Together, the immunofluorescence and gel electro-
phoresis studies demonstrate that a coexpressed ex-coexpressed expanded glutamine fragment. Quantita-
tion of colocalization showed that normal ataxin-3 es- panded glutamine fragment markedly alters the intracel-
lular behavior of full-length ataxin-3. In at least onesentially always colocalized with HA-Q78 to intracellular
spherical structures (in one experiment, 97 out of 97 important respect, the changes induced by the gluta-
mine fragment differ for normal and expanded ataxin-3.cells in randomly selected fields), and similar results
Intranuclear Inclusions in SCA3/MJD
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Figure 6. Recruitment of Expanded Ataxin-3
into Insoluble Aggregates
(A) Western blot of lysates from cells
transfected with HA-Q27 or HA-Q78 alone.
HA-Q78 forms insoluble complexes that mi-
grate in the stack and at the top of the sepa-
rating gel (arrowhead), while the normal gluta-
mine repeat HA-Q27 forms little if any
insoluble complex. Arrows indicate probable
monomeric forms of Q27 and Q78. Both also
generate higher molecular weight bands that
may be SDS-resistant dimers.
(B) Full-length expanded ataxin-3 is recruited
into insoluble complexes by coexpressed
HA-Q78. Lysates from transfected cells were
run in parallel on separate gels and probed
with: (left) 2B6, which recognizes full-length
ataxin-3 but not HA-Q27 or HA-Q78; and
(right) anti-HA antibody, which recognizes
HA-Q27, HA-Q78, and HA-ataxin78, but not
untagged ataxin27. Whereas expanded re-
peat ataxin-3 is recruited into insoluble com-
plexes (left panel, far right lane), normal re-
peat ataxin-3 is not (adjacent lane). Note that
endogenous ataxin-3 in 293T cells is recog-
nized by MAb2B6. Results are representative
of three experiments.
Whereas both normal and expanded ataxin-3 are re- product, ataxin-1 (H. Orr and H. Zoghbi, personal com-
munucation). Moreover, in transfected cells, expandedcruited by an expanded glutamine fragment into subcel-
ataxin-1 forms large intranuclear structures (H. Orr andlular structures, only expanded ataxin-3 is recruited into
H. Zoghbi, personal communication). In an HD trans-insoluble aggregates. The simplest interpretation is that
genic mouse, neuronal NI are formed by a truncatedthe intermolecular bonds formed between two glu-
huntingtin protein containing an expanded repeat (Da-tamine domains differ significantly, depending upon
vies et al., 1997). Because the transgene in this mousewhether both domains are expanded versus only one
model is only a single exon of the HD gene encodingof the two.
a small amino-terminal polyglutamine fragment of the
protein (Mangiarini et al., 1996), some might argue thatDiscussion
it does not precisely mirror the human disease.However,
similar intranuclear inclusions have already been notedWhile the geneticbasis of theCAG/polyglutamine repeat
in an earlier ultrastructural analysis of HD brain (Roizindiseases is clear, the molecular mechanism of neuronal
et al., 1979). The presence of NI in three separate CAG/degeneration remains uncertain. Our results from SCA3/
polyglutamine diseases or models of disease indicatesMJD tissue argue strongly for a protein-mediated effect
that thedisease process may becentered in the nucleus.as the basis of disease. In particular, the presence of
The distribution of NI in SCA3/MJD brain correspondsubiquitinated NI containing ataxin-3 suggests that ag-
to regions that are known to be affected in disease.gregation of the disease protein occurs within neurons.
Despite this clear and direct correlation, we cannot as-Although ataxin-3 is normally expressed widely in the
sume a causal link between the presence of NI and
CNS, there is a direct correlation between brain regions
neurodegeneration. Still, there are several plausible
that display NI and regions that are known targets in
ways NI might perturb neuronal function. It is increas-
disease, implying that neuronal NI are an integral part
ingly clear that nuclear events are exquisitely regulated
of the disease process. Together with recent evidence in a spatial and temporal manner. On mechanical
showing similar NI in transgenic models of other CAG/ grounds alone, NI could disrupt spatially coordinated
polyglutamine repeat diseases, our results suggest that nuclear processes such as transcription and splicing.
the nucleus is a primary site of pathogenesis in this Alternatively, NI might sequester important nuclear fac-
class of neurodegenerative disorders. tors, thereby altering gene expression. Because of its
own polymorphic glutamine repeat (Imbert et al., 1994),
The Nucleus as a Primary Site of Pathogenesis the TATA-binding protein is one potential candidate for
Are NI pathologic features shared by all CAG/polyglu- sequestration along with a polyglutamine disease pro-
tamine diseases? Recent studies of two other diseases tein. A third possibility is that the formation of NI reflects,
suggest that this may be the case. In the SCA1 or causes, a breakdown in normal proteolytic processes
transgenic mouse (Burright et al., 1995), degenerating within the nucleus. Proteosomes are abundant in the
nuclei of neurons (Mengual et al., 1996), suggesting thatPurkinje cells develop NI that contain the SCA1 gene
Neuron
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Figure 7. Cellular Redistribution of Ataxin-3 by Coexpressed HA-Q78
Paired coimmunofluorescence images of cells transfected with the indicated constructs (left) and immunolabeled with antibodies (top)
separately detecting HA-Q78 (anti-HA antibody) and the cotransfected protein. Both normal and expanded ataxin-3 normally distribute diffusely
in the cytoplasm but become localized to perinuclear structures when coexpressed with HA-Q78. The cellular distribution of two transfected
control proteins, b-galactosidase (shown at right) and calbindin (not shown), is not altered by coexpression of HA-Q78. Shown are representative
fields in all cases.
intranuclear proteolysis is one way for the cell to pre- in an inaccessible, insoluble form within NI. In SCA3/
MJD, NI must contain regions of the ataxin-3 proteincisely regulate the relative abundance of nuclear factors.
Even subtle changes in normal nuclear proteolysis might outside of the glutamine domain, because NI are labeled
by 1H9, an ataxin-3 specific MAb that fails to recognizeperturb this homeostasis. Further molecular analysis of
NI in SCA3/MJD should help determine whether nuclear the carboxy-terminal glutamine fragment of the protein.
WhetherNI include the full protein, however, isunknown.functions are disrupted.
NI apparently form in CAG/polyglutamine repeat dis- NI have been described in relatively few neurologic
disorders, including viral diseases, oculopharyngealeases regardless of the normal cellular distribution of the
protein. While ataxin-1 is normally found in the nucleus, muscular dystrophy (Blumen et al., 1996), and NIID (Palo
et al., 1984; Garen et al., 1986; Weidenheim and Dickson,both huntingtin and ataxin-3 are predominantly cyto-
plasmic proteins (DiFiglia et al., 1995; Gutekunst et al., 1995). Clinically, the lastof thesemost closely resembles
CAG/polyglutamine diseases. Some patients with NIID1995; Servadio et al., 1995; Sharp et al., 1995; Trottier
et al., 1995a; Paulson et al., 1997). In fact, further immu- develop progressive ataxia with extrapyramidal fea-
tures, also one of the most common clinical presenta-nocytochemical studies of ataxin-3 in cell lines indicate
that the protein's subcellular distribution is actually tions in several CAG/polyglutamine diseases. The two
can, however, be distinguished on several grounds.complicated and includes nuclear expression in a small
percentage of cells (M. Perez and H. Paulson, unpub- NIID, which is a rare and probably heterogeneous disor-
der, does not show the dominant inheritance pattern oflished data); and according to one report, huntingtin
may localize to the nucleus as well as the cytoplasm most CAG/polyglutamine diseases. Moreover, the inclu-
sions in NIID, unlike those in SCA3/MJD, areautofluores-(DeRooij et al., 1996). These facts raise an important
question: do NI derive from a normal nuclear pool of the cent, may contain neurofilament antigen, and are found
throughout the brain. Still, some cases of adult onsetdisease protein or from the larger cytoplasmic pool?
Equally important, does the disease protein within NI NIID could represent sporadic forms of CAG/polyglu-
tamine repeat diseases, a testable hypothesis now thatrepresent the full protein, a polyglutamine fragment, or
some combination? In CAG/polyglutamine diseases, the antibodies are available for expanded polyglutamine
tracts and many of the disease proteins.formation of polyglutamine-containing proteolytic frag-
ments of the disease protein has been proposed as the
mechanism of neurodegeneration (Goldberg et al., 1996; Ubiquitination in Disease
NI of ataxin-3 are disease-specific structures, and asIkeda et al., 1996). Although we have been unable to
detect proteolytic fragments of ataxin-3 in diseased such constitute a pathologic hallmark of SCA3/MJD.
The presence of ubiquitin, as well, in NI indicates thatbrain (Paulson et al., 1997), it is possible that they exist
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they likely represent pathologic aggregates of the dis- expanded ataxin-3, and (3) recruit expanded ataxin-3
into insoluble complexes. The last of these three de-ease protein. Although ubiquitination is a normal part
of the cell's proteolytic pathways, its occurrence in pends upon the presence of an expanded repeat in the
full protein, implying that recruitment into aggregatespathologic structures is thought to reflect misfolding,
aggregation, or aberrant degradation of proteins (Lowe occurs via direct interactions between glutamine do-
mains. Subcellular redistribution of full-length ataxin-3et al., 1993; Galvin et al., 1997). Except for a single report
showing ubiquitination of huntingtin (Kalchman et al., also may be mediated directly through the glutamine
domain, since control proteins lacking polyglutamine do1996), very little is known about the normal degradation
of polyglutamine disease proteins. It will be important not undergo cellular redistribution. We conclude that,
in vitro, a pathologic polyglutamine fragment can serveto determine whether ataxin-3 normally is degraded via
the ubiquitin-proteosome pathway, and whether this as the seed or catalyst for glutamine-mediated aggrega-
tion of the full protein. If similar events take place inpathway is disrupted or altered by an expanded gluta-
mine domain. Currently, it is unknown whether the ubi- vivo, the CAG/polyglutamine repeat diseases may prove
analogous to prion diseases, in which protease-resis-quitin within NI is covalently attached to ataxin-3 or to
other proteins. Further biochemical analysis of ataxin-3 tant forms of prion can induce misfolding and/or aggre-
gation of the normal prion protein (Come et al., 1993;inclusions should help determine whether the disease
protein is directly ubiquitinated and whether compo- DeArmond and Prusiner, 1995).
An intriguing feature of CAG/polyglutamine diseasesnents of the proteosome are sequestered within these
structures. is their cell specificity. Each disease causes degenera-
tion only of neurons, and only in selective brain regions,In SCA3/MJD, both the ubiquitin-positive NI and the
presumably extracellular ubiquitin deposits are found despite widespread expression of the disease protein.
Although higher expression levels of the disease proteinonly in affected brain regions, indicating that ubiquitina-
tion is either an integral part of, or at the very least a in susceptible populations of neurons may contribute
to this cell specificity, as has been reported inHD (Kosin-direct consequence of, the disease process. Our results,
together with results showing ubiquitin in the NI of HD ski et al., 1997), this can only be part of the answer. Our
results suggest that a pathogenic element in SCA3/MJDtransgenic mice (Davies et al., 1997), imply that ubiquiti-
nation may be a general feature of CAG/polyglutamine is the intranuclear aggregation of ataxin-3 in susceptible
neurons. Based on our in vivo and in vitro studies, wediseases. It will be important to determine whether ubiq-
uitination is seen in pathologic material from other CAG/ propose that cell specificity is in part determined by
differing propensities for ataxin-3 aggregation in differ-polyglutamine diseases. Unfortunately, human disease
tissue provides us with only a single glimpse in time of ent neuronal populations. In a subset of neurons, aggre-
gation would be promoted by any of the following: (1)the last stage in the disease process. Based on our
current studies of disease tissue, for example, we can- increased production of a proteolytic glutamine frag-
ment; (2) increased misfolding of the nascent polypep-not know whether the ubiquitin deposits seen in the
parenchyma of SCA3/MJD represent the end result of tide or unfolding of the mature protein; (3) increased
targeting of ataxin-3, or a proteolytic fragment, to theneurodegeneration. Careful and systematic analysis of
transgenic models of disease will help determine the nucleus; and (4) increased total expression of ataxin-3.
The last of these not only would raise local concentra-temporal relation of ubiquitination to cell death.
If ubiquitinated NI contain aggregated ataxin-3, why tions of the disease protein (perhaps thereby promoting
self-aggregation), but in the process might lead to andon't we observe high molecular weight complexes of
ataxin-3 on electrophoretic analysis of disease tissue? increase in pathways (1) through (3) as well.
A widely held view is that cell specificity in CAG/poly-We suspect that NI from diseased brain remain insoluble
with standard techniques of homogenization, lysis, and glutamine repeat diseases arises, in part, from differ-
ences among neurons in the set of proteins that normallysample preparation, and thus are too large to enter the
stack of an SDS-polyacrylamide gel. If we succeed in interact with the disease protein. This view and our pro-
posed aggregation model are not mutually exclusive.developing denaturation procedures that can dissociate
the insoluble complexes formed in vitro, the same dena- On the contrary, normal interacting proteins might be
expected to influence the disease protein's subcellularturation procedures will be applied to homogenates
from disease brain. It is possible, however, that the distribution, rate of degradation, probability of misfold-
aggregates formed in vitro and in vivo are covalently ing, and, most important, the degree to which its gluta-
linked by transglutaminase-mediated crosslinking (Green, mine domain is exposed or sequestered. Any or all of
1993; Kahlem et al., 1996), in which case dissociation these events could, in turn, influence the rate of aggre-
may be impossible. gation.
Aggregation and Its Relationship to Cell Specificity Experimental Procedures
Because of our in vivo studies showing NI of ataxin-3,
we sought todevelop an in vitro model of polyglutamine- Pathologic Tissue
A total of six SCA3/MJD brains were examined, two cases eachmediated aggregation. While no in vitro model can fully
from three unrelated families (in all of whom expansion of the MJD1replicate a disease process occurring over decades,
triplet repeat has been confirmed). The five control brains includedour results provide insight into possible mechanisms of
three individuals without a history of neurologic illness and two
aggregation in the disease state. In transfected cells, individuals with a history of Alzheimer's disease as irrelevant disease
we have shown that a pathologic (expanded) glutamine controls. The shortest postmortem interval for an SCA3/MJD brain
fragment can (1) form intranuclear and perinuclear com- was ,1 hr, and the longest was 22 hr; these two brains showed a
similar frequency of NI.plexes, (2) cause a cellular redistribution of normal or
Neuron
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Immunohistochemistry and Immunofluorescence Expression Constructs and Transfection
For most transfections, we used the expression vector pCDNA3The antibodies and dilutions used in this study are shown in Table
containing either full-length or truncated ataxin-3. Constructs en-2. Ataxin-3 polyclonal antiserum has been described (Paulson et
coding full-length ataxin-3 with 27 or 78 CAG repeats, pCDNA3-al., 1997). MAbs 1H9 and 2B6 specifically bind ataxin-3 at regions
MJD27 and pCDNA-HAMJD78, were previously described (Paulsonamino-terminal to the glutamine tract and will be described in detail
et al., 1997); the latter has an HA epitope at the amino terminusin a separate publication (Trottier et al., unpublished data). Epitope
of the protein. Truncated ataxin-3 constructs were generated bytag antibodies used in this study were the anti-hemagglutinin (HA)
digesting ataxin-3 cDNA at the Xmn1 site, 39 bp upstream of theantibodies 12CA5 (Boehringer Mannheim) and Y11 (generously pro-
CAG repeat, and placing the resultant carboxy-terminal ataxin-3vided by D. Merry, Philadelphia) and the anti-myc antibody 9E10
fragment into the Sma1 site of the HA-tagging vector pJ3H (ATCC).(Calbiochem).
The resulting truncated ataxin-3 protein consists of an amino-termi-For immunohistochemistry of brain sections, 6 mm sections of
nalHA epitope, 12 amino acids of ataxin-3upstream of the glutamineparaffin-embedded tissue were processed and stained using the
repeat, the glutamine repeat (27 or 78 repeats), and the 43 aminoperoxidase-DAB technique as previously described (Paulson et al.,
acids comprising the carboxy-terminus of the protein. This HA-1997). Sections were typically counterstained with hematoxylin. In
tagged construct was then subcloned into pCDNA3 for transfectioncontrol experiments, the ataxin-3 polyclonal antiserum, anti-ubiqui-
studies (pCDNA-HAQ27 and pCDNA-HAQ78). Myc-tagged full-tin antiserum, and MAbs 1H9 and 1C2 were screened against sec-
length ataxin-3 with 78 repeats was generated by subcloningtions of normal pons to ensure that the recognized NI were specific
ataxin-3 cDNA from pCDNA-HAMJD78 into the BamH1 site of pJ3Mfor disease tissue. All four antibodies specifically stained NI both
(ATCC), thus replacing the HA epitope with a myc epitope at theby immunofluorescence and by immunohistochemistry. All other
amino terminus.antibodies shown in Table 2 were screened against appropriate
Subconfluent 293T cells were transfected using calcium phos-control brain sections, to verify that the specific antigen was de-
phate precipitation (Sambrook et al., 1989). Twenty-four hours aftertected at the concentration used.
transfection, cells were plated onto cover slips; 12 hr later, they
For coimmmunofluorescence studies of brain tissue, sections
were processed for immunofluorescence. Cells were fixed with 4%
were labeled with primary antisera, followed by fluorescein isothio-
paraformaldehyde, permeabilized with 0.05% Triton X-100, and in-
cyanate (FITC) goat anti-rabbit and rhodamine-goat anti-mouse cubated in a blocking solution (2% normal goat serum in PBS with
sera, and viewed under standard epifluorescence with an XL-70 0.05% Triton X-100) prior to incubations with antibody.
Minolta microscope or with a Leika LSBM laser confocal system In some experiments, transfected cells were labeled with the or-
coupled to a Leitz microscope. In confocal studies, we verified that ganelle-specific dyes Lysotracker red DND-99 (50 nM) and Mito-
no signal was obtained through the rhodamine channel after excita- tracker green FM (200 nM; Molecular Probes) for 60 min prior to
tion for FITC, thus ensuring that signal crossover did not occur. fixation. In these experiments, fixed cells were extracted with ice
FITC and rhodamine channels were collected simultaneously, and cold acetone, as recommended by the manufacturer, prior to subse-
the digitized images were pseudocolored and recombined using quent immunofluorescence.
Adobe Photoshop. For standard immunofluorescence, photo-
graphic slides were taken, scanned into digitized images, and pro- Cell Viability
cessed with Adobe Photoshop. In three similar experiments, 35 mm plates of cells were cotrans-
MAb 1C2 recognizes expanded polyglutamine in ataxin-3 and fected with 2 mg total plasmid DNA in a 1:4 ratio of RSV-bGal to one
other polyglutamine disease proteins (Trottier et al., 1995b) but also of the following: pCDNA-MJD78, pCDNA-MJD27, pCDNA-HAQ27,
recognizes the glutamine repeat of TATA-binding protein, the pro- pCDNA-HAQ78, or pCDNA3 control plasmid. Viability was assessed
tein against which it was initially raised (Lescure et al., 1994). How- by changes in the morphology of b-galactosidase-positive cells. At
ever, at very low concentrations of the antiserum, 1C2 specifically 48 and 72 hr after transfection, cells were washed inPBS, fixed in 4%
binds to expanded glutamine tracts (I. An and E. Hirsch, personal paraformaldehyde and stained with X-Gal. Blue cells were scored as
communication). Therefore, in some immunohistochemistry experi- apoptotic or healthy (i.e., nonapoptotic), based on morphological
ments of brain tissue, and in all immunofluorescence studies of criteria: small, round blebbing cells were scored as apoptotic and
transfected cells, a 1:15,000 dilution of 1C2 was used. Immunohisto- all other cells as healthy. For each sample, ten random fields were
scored in a blinded manner. Cells transfected with HA-Q78 consis-chemical staining of NI was still present (albiet weaker) even at
tently showed an approximately threefold increase in apoptotic ap-this lower concentration, confirming that the pathological expanded
pearing cells when compared to all other transfected ataxin-3 con-glutamine epitope of ataxin-3exists within NI. For coimmunofluores-
structs (see Figure 5C).cence experiments of human tissue, a 1C2 dilution of 1:400 was
used.
Quantitation of In Vitro Complexes
In cotransfection experiments, ten randomly selected fields of im-
munofluorescently labeled cells were viewed under FITC filter andQuantitation of NI
scored for the total number of transfected cells expressing HA-Q78Four SCA3/MJD cases were chosen for analysis, based on the avail-
or HA-Q27 and then for the number of positive cells in which stainingability of equivalent sections through ventral mid-pons. Thin paraffin
was punctate (close to 100% for HA-Q78 and 0% for HA-Q27). Thesections of ventral pons from four SCA3/MJD individuals (three
same fields were then viewed with the rhodamine filter, allowing usseparate families) and five controls were labeled immunohistochem-
to determine the percent of ataxin27- or ataxin78-expressing cellsically with affinity-purified ataxin-3 antiserum and scored for NI by
(stained with anti-myc or 2B6) that showed precise colocalizationan observer educated in the appearance of inclusions but blinded
to spherical structures. Quantitation was performed ina similarman-to the origin of the sections. In randomly selected sweeps at 4003,
ner for cells transfected singly with ataxin27, ataxin78, HA-Q27, andall pontine neurons in which the nucleus clearly was seen in cross
HA-Q78, and for control cotransfections with HA-Q78 and calbindin
section were scored for the presence or absence of immunohisto-
or b-galactosidase. On average, z100 cells werecounted per exper-
chemically stained intranuclear spherical bodies. (To be seen and imental sample.
scored as a distinct structure, the diameter of an inclusion must be
z0.5 mm or greater.) Neurons (110±150) were scored in each brain, Gel Electrophoresis and Western Blot Analysis
and the percentage of neurons containing inclusions was deter- Transfected cells were solubilized and prepared for SDS-polyacryl-
mined for each sample. A mean percent value was then calculated, amide gel electrophoresis as described (Paulson et al., 1997). Equal
shown in Table 1. volumes of equivalent lysates were electrophoresed on discontinu-
In one SCA3/MJD brain (the case described by Paulson et al., ous 10% polyacrylamide gels, and both the separating and stacking
1997), we quantitated inclusions from adjacent regions of ventral portions of the gel were transblotted to polyvinylidene difluoride
pons that had been fixed separately with 70% ethanol/saline or 4% (PVDF) membrane (DuPont, New England Nuclear). Blots were incu-
paraformaldehyde. Essentially identical results were obtained for bated with affinity-purified ataxin-3 antiserum (1:1000), MAb 2B6
both fixatives, confirming that the number of NI is independent of (1:1000) or anti-HA MAb 12CA5 (1:3000) in 5% nonfat milk/PBS,
followed by horseradish peroxidase-conjugated goat anti-rabbitthe method of fixation.
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(1:1000) or goat anti-mouse (1:10,000) antiserum. In some experi- al. (1996). Spinocerebellar ataxia 3 and Machado-Joseph disease:
clinical, molecular and neuropathologic features. Ann. Neurol. 39,ments (e.g., Figure 6), identical protein samples were run on separate
gels and immunoblotted with separate antibodies in parallel. In oth- 490±499.
ers, blots were stripped and reprobed with a second antibody; strip- Galvin, J.E., Lee, V.M.-Y., Schmidt, M.L., Tu, P.-H., Iwatsubo, T.,
ping involved incubating blots 20 min at 458C in 62.5 mM Tris-HCl and Trojanowski, J.Q. (1997). Pathobiology of the Lewy body (LB);
(pH 6.8), 2% SDS, and 100 mM b-mercaptoethanol, followed by studies of purified LBs, monoclonal antibodies and LB-like inclu-
extensive washing in PBS. Immunoreactive bands were visualized sions in transgenic animal models. Adv. Neurol., in press.
by chemiluminescence (Renaissance, Du Pont-NEN). Garen, P.D., Powers, J.M., Young, G.F., and Lee, V. (1986). Neuronal
intranuclear hyaline inclusion disease in a nine year old. Acta. Neuro-
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